- Formation of Proteo Biotech AG, spin-off of the University of Kiel, Germany
- Proteo Biotech AG entered into a reorganization and stock exchange agreement with Proteo, Inc., USA,
and as a result Proteo Biotech AG became a wholly owned subsidiary of Proteo, Inc.
- State of Schleswig-Holstein funds Elafin development project of Proteo Biotech AG.
- Development of Elafin production under laboratory conditions with competent biotechnology enterprises
- Proteo granted approval to operate gene technology facility
- First marketing activities with the Dutch biotech-company HyCult Biotechnology B.V.
- Successful completion of studies on acute toxicity of Elafin in mice and rats
- Official inauguration of the Proteo Biotech plant in Kiel
- An additional 760.000 EUR funding has been provided through an European regional development program (
EFRE) for further development of Elafin.
- Research-Collaboration-Agreement between the Charité Berlin and Proteo Biotech AG
- Exclusive License- and Collaboration- Agreement with Artes Biotechnology GmbH for an expression
- First Production of Elafin for clinical testing
- Elafin was successfully tested in a Phase I clinical trial.
- Strategic alliance for marketing of Elafin in Asia, Africa and South America with Artes Biotechnology GmbH
- Elafin ranked as a Top 10 Cardiovascular Drug Development
- European Commission grants Orphan Drug Status to Elafin for the treatment of PAH.
- Proteo cooperates with the University of Alberta.
- Proteo and Minapharm, Egypt, entered into a license agreement for clinical development, production and
marketing of Elafin in Egypt, Middle Eastern and African countries.
- Proteo cooperates with Stanford University.
- Start Phase II clinical trial with Elafin in patients undergoing esophagectomy for esophagus carcinoma
- Cooperation with the University of Edinburgh to investigate the effect of Elafin on the damage and inflammation of cardiac muscle after coronary bypass operations in a Phase II clinical trial
- Clinical study in Harvard reveals Elafin deficiency in acute respiratory distress syndrome (ARDS).
- European Commission grants Orphan Drug Designation for the protease inhibitor Elafin for the treatment of oesophagus carcinoma.
- Successful completion of patient recruitment for the Phase II clinical trial on Elafin in patients with esophagus cancer
- Proteo cooperates with Molecular Imaging North Competence Center (MOIN CC).
- The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) tested Proteo’s Elafin.
- Results Phase II clinical trial: Elafin shortens intensive care after surgery for esophagus cancer
- Start Phase II clinical trial with Elafin in patients undergoing coronary bypass surgery
- NIH supports the Elafin development program for lung diseases at Stanford University with a $10.8 million grant.
- 75% of subjects recruited for the Phase II clinical trial on Elafin in patients undergoing coronary bypass surgery
- FDA grants Orphan Drug Designation for Elafin for the treatment of pulmonary arterial hypertension.
- FDA grants Orphan Drug Designation for Elafin for the prevention of inflammatory complications of transthoracic esophagectomy.
- Patient recruitment for the Phase II clinical trial on Elafin in patients undergoing coronary bypass surgery completed
- $ 4.8 million funding for Proteo's Advanced Orphan Drug Development
- Results Phase II clinical trial in patients undergoing coronary bypass surgery: Significant reduction of cardiac troponin I within first 6 hours after Elafin treatment. The favorable safety profile of Elafin was confirmed. Statistical significance on the primary endpoint could not be demonstrated.
- In a mouse model, Elafin and cyclosporine A act synergistically to prevent the development of irreversible damage to transplanted lung tissue.
- Elafin reverses obliterative changes in explanted lung tissue from PAH patients.
- In December, the EMA paediatric committee (PDCO) adopted a positive opinion regarding Proteo's application for a product-specific paediatric investigation plan (PIP) waiver for Tiprelestat in the treatment of oesophageal carcinoma.
PROTEO BIOTECH AG
Am Kiel-Kanal 44
phone: +49 431 8888462
https://proteo.de/pages/company/history.html – printed on 2018-02-01 9:03:20